InflaRx N.V.
NASDAQ:IFRX · NASDAQ Global Select
-$0.02 today
Vol 1.46M · Avg 1.80M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$43.8M +4.8% | -$46.1M -8.0% | -$42.7M -44.7% | -$29.5M +35.4% | -$45.6M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $402.9K -16.9% | $485.1K -14.6% | $567.8K -4.8% | $596.6K -10.9% | $669.4K | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 -100.0% | $1.2M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $0 -100.0% | $4.1M +19.1% | $3.4M -43.5% | $6.0M +39.5% | $4.3M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | $4.7M +304.7% | -$2.3M -327.0% | $1.0M +110.3% | -$9.8M -735.4% | $1.5M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $2.1M | $0 | $0 | $0 | $0 | $592.6M | $1.3B | $626.2M |
| Inventory | $6.6M +48.2% | $4.5M +139.3% | -$11.4M | $0 | $0 | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$5.8M | $0 | $0 +100.0% | -$3.5M -1214.2% | $316.1K | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $1.7M +124.9% | -$6.7M -154.6% | $12.4M +297.9% | -$6.3M -611.5% | $1.2M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $4.8M +201.7% | -$4.8M -3529.1% | -$131.3K +88.3% | -$1.1M +43.9% | -$2.0M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$33.9M +30.1% | -$48.6M -28.4% | -$37.8M -12.1% | -$33.7M +15.5% | -$39.9M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$111.1K -137.1% | -$46.9K +42.2% | -$81.1K +50.1% | -$162.4K -329.9% | -$37.8K | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 +100.0% | -$19.5M -51771.6% | $37.8K | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$44.3M -25.3% | -$35.3M +66.0% | -$104.1M -61.4% | -$64.5M +33.9% | -$97.5M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $47.5M -45.9% | $87.8M +1.5% | $86.4M +2.9% | $84.0M +17.3% | $71.6M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$3 -400.0% | $1 | $0 -100.0% | $19.5M +51771.6% | -$37.8K | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $3.1M -94.1% | $52.4M +395.9% | -$17.7M -191.4% | $19.4M +174.6% | -$26.0M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | -$357.6K +7.9% | -$388.1K -3.8% | -$374.0K -2.6% | -$364.4K -1.0% | -$360.6K | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $32.3M +2845.1% | $1.1M -98.1% | $56.5M +2304.0% | $2.3M -96.4% | $65.1M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $14.1K +104.4% | -$323.7K +89.6% | -$3.1M -6443.8% | -$47.7K +98.5% | -$3.2M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $32.0M +8181.0% | $386.4K -99.3% | $53.0M +2634.8% | $1.9M -96.9% | $61.6M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | -$1.4M -196.6% | $1.4M +245.2% | -$974.1K -139.6% | $2.5M -46.4% | $4.6M | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$179.7K -103.2% | $5.6M +260.3% | -$3.5M +65.0% | -$10.0M -3649.3% | $281.3K | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$34.0M +30.0% | -$48.6M -28.3% | -$37.9M -11.8% | -$33.9M +15.2% | -$40.0M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Sutro Biopharma, Inc.
NASDAQ:STRO
$283.06M
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
$234.93M
Shattuck Labs, Inc.
NASDAQ:STTK
$232.33M
Connect Biopharma Holdings Limited
NASDAQ:CNTB
$125.61M
Kalaris Therapeutics Inc
NASDAQ:KLRS
$89.77M
ImageneBio Inc
NASDAQ:IMA
$68.52M
Context Therapeutics Inc.
NASDAQ:CNTX
$56.81M
Metagenomi, Inc. Common Stock
MGX
$45.93M
aTyr Pharma, Inc.
ATYR
$45.03M
Quince Therapeutics, Inc.
QNCX
$5.03M
SEC Filings
Recent regulatory filings
No filings found.
Does IFRX generate free cash flow?
InflaRx N.V. (IFRX) generated -$34,031,693.00 of free cash flow in fiscal 2025.
How much operating cash flow does IFRX produce?
Operating cash flow was -$33,920,565.00, before capital expenditures of $111,127.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.